BspQ I
BspQ I creates linearized, scarless templates from plasmid DNA suitable for use in in vitro transcription. As a type IIS restriction enzyme that cleaves DNA outside its recognition site, the use of BspQ I to linearize plasmid DNA ensures that the 3′ end of the in vitro transcription template does not contain extra base pairs from the restriction site.
BspQ I creates linearized, scarless templates from plasmid DNA suitable for in in vitro transcription. As a type IIS restriction enzyme that cleaves DNA outside its recognition site, the use of BspQ I to linearize plasmid DNA ensures that the 3′ end of the in vitro transcription template does not contain extra base pairs from the restriction site. This keeps the template poly(A) sequence intact and promotes successful translation after mRNA synthesis.
BspQ I, HQ (high quality) has been manufactured with stricter quality standards and is supplied in a higher concentration and volume scaling up your processes. It is free from human- or animal-derived materials, as well as free from β-lactam compounds in the final formulation.
Do you want to explore OEM options? Contact OEM Services & Support at oem@takarabio.com.
For more information on the differences between our research, HQ, and GMP grade enzymes, please refer to the HQ-grade reagents page.
Overview
Perfect for preparing scarless in-vitro transcription templates from plasmid DNA
- Cuts outside recognition site keeping the poly(A) tail sequence intact, which promotes successful translation downstream of the in vitro transcription
- Linearizes plasmid DNA in one hour
- Comes in an HQ version to support a smooth transition from RUO to GMP grade RNA manufacturing
More Information
Applications
Linearization of plasmid DNA for use as a template for in vitro transcription.
Source
Escherichia coli carrying the plasmid containing the gene for BspQ I.
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Speed up your vaccine development with innovative technologies
Vaccines have significantly decreased the burden of infectious diseases worldwide since the development of the first vaccine more than 200 years ago that led to the eradication of smallpox. In recent years, the spread of severe infections has highlighted the critical need for the rapid development of vaccines against previously unknown pathogens to deal with pandemics such as COVID-19.
Discover how Takara Bio can help speed up your vaccine-development process.
Learn more
Powered by BiozTakara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2026 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
